Menu Search
Equities

D.Western Therapeutics Institute Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6DW:FRA

D.Western Therapeutics Institute Inc

Actions
  • Price (EUR)0.50
  • Today's Change0.014 / 2.88%
  • Shares traded141.00
  • 1 Year change-37.11%
  • Beta1.2222
Data delayed at least 15 minutes, as of Feb 10 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.

  • Revenue in JPY (TTM)419.76m
  • Net income in JPY-1.06bn
  • Incorporated1999
  • Employees21.00
  • Location
    D.Western Therapeutics Institute Inc1-18-11, NishikiNAGOYA-SHI 460-0003JapanJPN
  • Phone+81 522188785
  • Fax+81 522021866
  • Websitehttps://dwti.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.